• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


Intertek banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Hikma to market Orion’s budesonide/formoterol Easyhaler in the Middle East and North Africa

According to Hikma Pharmaceuticals, the company has signed a licensing and distribution agreement with Orion Corporation for marketing rights to a budesonide/formoterol Easyhaler DPI for the treatment of asthma and COPD throughout the Middle East and North Africa (MENA).

Hikma Vice Chairman and CEO of MENA and Emerging Markets Mazen Darwazah commented, “We are pleased to be adding this important product to our respiratory pipeline and we hope this collaboration with Orion will be the beginning of a long partnership for its Easyhaler device products in the MENA region. Global partnerships are an integral part of our strategy to grow our portfolio in key therapeutic areas and improve patients’ access to high-quality medicines.”

Orion Senior VP of Proprietary Products Markku Huhta-Koivisto said, “I am excited about this collaboration between Orion and Hikma and look forward to having such a strong partner in the MENA region supporting the expansion of our Easyhaler business. This collaboration is also an excellent opportunity to deepen our longstanding relationship with Hikma. We’re confident that the good momentum we have for our Easyhaler products will continue and that this partnership with Hikma will, for its part, strengthen Orion’s strategic objective to become a stronger player in the field of respiratory medication.”

Read the Hikma press release.

Share

published on February 14, 2017

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Catalent banner
    © 2025 OINDPnews